All Brands Owned by Jazz Pharmaceuticals

What does Jazz Pharmaceuticals make?
Jazz Pharmaceuticals makes prescription therapies in neuroscience and oncology. Key products include Xywav and Xyrem for sleep disorders (narcolepsy, idiopathic hypersomnia, cataplexy), Epidiolex for seizures associated with epilepsy, Rylaze for acute lymphoblastic leukemia, Zepzelca for small cell lung cancer, Defitelio for hepatic veno-occlusive disease, Vyxeos for acute myeloid leukemia, Modeyso for multiple myeloma, and Ziihera for HER2-positive cancers.

Is Jazz Pharmaceuticals publicly traded?
Yes, Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker symbol JAZZ. The company is incorporated in Ireland and headquartered in Dublin. It has been listed on Nasdaq since its IPO in 2007.

Who founded Jazz Pharmaceuticals?
Jazz Pharmaceuticals was founded in 2005 by Bruce Cozadd, who previously served as Executive Vice President and Chief Operating Officer at ALZA Corporation. Cozadd continues to serve as Chairman and CEO, making him one of the longest-serving founders still leading a major pharmaceutical company.

Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland. The company is incorporated in Ireland for tax and regulatory purposes. Its major operational hubs are in Palo Alto, California and Philadelphia, Pennsylvania, with additional offices in Europe and Canada. Manufacturing is conducted at facilities in Ireland, Italy, and the United States.

How many employees does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals employed approximately 2,890 people as of 31 December 2025. The company's workforce is distributed across research and development, manufacturing, commercial operations, and corporate functions.

Who owns Jazz Pharmaceuticals?
Jazz Pharmaceuticals plc is publicly traded on Nasdaq under the ticker JAZZ. The company has a broad institutional shareholder base with no single controlling shareholder. Major shareholders include institutional investors such as Vanguard Group, BlackRock, and State Street Corporation, consistent with the ownership profile of mid-cap pharmaceutical companies.

What is Xywav?
Xywav is Jazz Pharmaceuticals' largest product by revenue, generating $1.66 billion in net sales in 2025. It is a calcium, magnesium, potassium, and sodium oxybate formulation approved for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy and for idiopathic hypersomnia. Xywav contains less sodium than Xyrem, addressing cardiovascular concerns associated with high sodium intake.